Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation
Launched by HOSPITAL UNIVERSITARIO DR. JOSE E. GONZALEZ · Mar 21, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
The objective of this study is to demonstrate that the use of a low dose of the generic form of a drug called plerixafor is effective in increasing the amount of hematopoietic cells (stem cells) in your blood, which will then be collected for your transplant. Plerixafor is a very effective medicine that is already used for this purpose, however its high cost limits its use in all patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with lymphoma or multiple myeloma who are candidates for autoHSCT
- • Patients \> 18 years old who signed our informed consent
- • Normal CBC count (Hb \> 10, WBC 4.0-11.00, plt \> 100,000)
- Exclusion Criteria:
- • Patients with HIV, Hepatitis C, Hepatitis B diagnosis
- • Pregnant women
About Hospital Universitario Dr. Jose E. Gonzalez
Hospital Universitario Dr. José E. González is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. Located in Monterrey, Mexico, the hospital is affiliated with the University of Nuevo León, fostering a collaborative environment that integrates education, patient care, and scientific inquiry. With a commitment to improving patient outcomes, the hospital actively conducts clinical trials across various medical disciplines, leveraging its state-of-the-art facilities and a multidisciplinary team of experts to explore new therapies and enhance treatment options for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Monterrey, Nuevo Leon, Mexico
Patients applied
Trial Officials
Olga G Cantú-Rodríguez, MD
Study Chair
Universidad Autónoma de Nuevo León
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported